KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) EBIT Margin (2018 - 2026)

Castle Biosciences' EBIT Margin history spans 8 years, with the latest figure at 4.4% for Q4 2025.

  • On a quarterly basis, EBIT Margin fell 909.0% to 4.4% in Q4 2025 year-over-year; TTM through Dec 2025 was 12.44%, a 1505.0% decrease, with the full-year FY2025 number at 12.44%, down 1505.0% from a year prior.
  • EBIT Margin hit 4.4% in Q4 2025 for Castle Biosciences, up from 8.19% in the prior quarter.
  • Over the last five years, EBIT Margin for CSTL hit a ceiling of 5.92% in Q3 2024 and a floor of 91.3% in Q1 2022.
  • Historically, EBIT Margin has averaged 28.53% across 5 years, with a median of 17.23% in 2023.
  • Biggest five-year swings in EBIT Margin: plummeted -7252bps in 2022 and later skyrocketed 6749bps in 2024.
  • Tracing CSTL's EBIT Margin over 5 years: stood at 60.59% in 2021, then rose by 2bps to 59.55% in 2022, then soared by 86bps to 8.56% in 2023, then skyrocketed by 155bps to 4.69% in 2024, then tumbled by -194bps to 4.4% in 2025.
  • Business Quant data shows EBIT Margin for CSTL at 4.4% in Q4 2025, 8.19% in Q3 2025, and 4.93% in Q2 2025.